Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Determinants of fibrosis progression and regression in NASH
Detlef Schuppan, Rambabu Surabattula, Xiaoyu Wang
Journal of Hepatology (2017) Vol. 68, Iss. 2, pp. 238-250
Closed Access | Times Cited: 419

Showing 26-50 of 419 citing articles:

Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non‐alcoholic fatty liver disease assessed by magnetic resonance imaging
Anne Flint, Grit Andersen, Paul Hockings, et al.
Alimentary Pharmacology & Therapeutics (2021) Vol. 54, Iss. 9, pp. 1150-1161
Open Access | Times Cited: 143
Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease
Ramy Younes, Gian Paolo Caviglia, Olivier Govaere, et al.
Journal of Hepatology (2021) Vol. 75, Iss. 4, pp. 786-794
Closed Access | Times Cited: 142
Non-alcoholic fatty liver disease: Definition and subtypes
Seulki Han, Soon Koo Baik, Moon Young Kim
Clinical and Molecular Hepatology (2022) Vol. 29, Iss. Suppl, pp. S5-S16
Open Access | Times Cited: 107
Understanding the cellular interactome of non-alcoholic fatty liver disease
Sebastian Wallace, Frank Tacke, Robert F. Schwabe, et al.
JHEP Reports (2022) Vol. 4, Iss. 8, pp. 100524-100524
Open Access | Times Cited: 79
MiR-690 treatment causes decreased fibrosis and steatosis and restores specific Kupffer cell functions in NASH
Hong Gao, Zhongmou Jin, Gautam Bandyopadhyay, et al.
Cell Metabolism (2022) Vol. 34, Iss. 7, pp. 978-990.e4
Open Access | Times Cited: 76
4. Comprehensive Medical Evaluation and Assessment of Comorbidities: Standards of Care in Diabetes—2024
Nuha A. ElSayed, Grazia Aleppo, Raveendhara R. Bannuru, et al.
Diabetes Care (2023) Vol. 47, Iss. Supplement_1, pp. S52-S76
Open Access | Times Cited: 74
Advances in the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease
Xunzhe Yin, Xiangyu Guo, Zuojia Liu, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2844-2844
Open Access | Times Cited: 46
Role of Insulin Resistance in the Development of Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: From Bench to Patient Care
Juan Patricio Nogueira, Kenneth Cusi
Diabetes Spectrum (2024) Vol. 37, Iss. 1, pp. 20-28
Open Access | Times Cited: 41
Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases
Yao Yu, Jingjing Cai, Zhi‐Gang She, et al.
Advanced Science (2018) Vol. 6, Iss. 4
Open Access | Times Cited: 149
Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials
Elizabeth M. Brunt, David E. Kleiner, Laura Wilson, et al.
Hepatology (2018) Vol. 70, Iss. 2, pp. 522-531
Open Access | Times Cited: 132
Annexin A5 regulates hepatic macrophage polarization via directly targeting PKM2 and ameliorates NASH
Fang Xu, Mengmeng Guo, Wei Huang, et al.
Redox Biology (2020) Vol. 36, pp. 101634-101634
Open Access | Times Cited: 118
Astaxanthin attenuates hepatic damage and mitochondrial dysfunction in non‐alcoholic fatty liver disease by up‐regulating the FGF21/PGC‐1α pathway
Liwei Wu, Wenhui Mo, Jiao Feng, et al.
British Journal of Pharmacology (2020) Vol. 177, Iss. 16, pp. 3760-3777
Open Access | Times Cited: 105
Nonalcoholic steatohepatitis (NASH) – current treatment recommendations and future developments
Elke Roeb, Andreas Geier
Zeitschrift für Gastroenterologie (2019) Vol. 57, Iss. 04, pp. 508-517
Closed Access | Times Cited: 85
Metabolic inflammation as an instigator of fibrosis during non-alcoholic fatty liver disease
Angeliki Katsarou, Ioannis I. Moustakas, Iryna Pyrina, et al.
World Journal of Gastroenterology (2020) Vol. 26, Iss. 17, pp. 1993-2011
Open Access | Times Cited: 81
Unraveling the Role of Leptin in Liver Function and Its Relationship with Liver Diseases
Maite Martinez‐Uña, Yaiza López‐Mancheño, Carlos Diéguez, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 24, pp. 9368-9368
Open Access | Times Cited: 80
Pharmacological Treatment for Non-alcoholic Fatty Liver Disease
Sven Francque, Luisa Vonghia
Advances in Therapy (2019) Vol. 36, Iss. 5, pp. 1052-1074
Open Access | Times Cited: 79
Role of Leptin in Non-Alcoholic Fatty Liver Disease
Carlos Jiménez‐Cortegana, Alba García-Galey, Malika Tami, et al.
Biomedicines (2021) Vol. 9, Iss. 7, pp. 762-762
Open Access | Times Cited: 71
Dopamine receptor D2 antagonism normalizes profibrotic macrophage-endothelial crosstalk in non-alcoholic steatohepatitis
Jie Qing, Yafeng Ren, Yuwei Zhang, et al.
Journal of Hepatology (2021) Vol. 76, Iss. 2, pp. 394-406
Closed Access | Times Cited: 67
The multifactorial mechanisms of bacterial infection in decompensated cirrhosis
Van der Merwe, Shilpa Chokshi, Christine Bernsmeier, et al.
Journal of Hepatology (2021) Vol. 75, pp. S82-S100
Closed Access | Times Cited: 65
Longitudinal 16S rRNA Sequencing Reveals Relationships among Alterations of Gut Microbiota and Nonalcoholic Fatty Liver Disease Progression in Mice
Aoxiang Zhuge, Shengjie Li, Pengcheng Lou, et al.
Microbiology Spectrum (2022) Vol. 10, Iss. 3
Open Access | Times Cited: 65
Insights into Manganese Superoxide Dismutase and Human Diseases
Mengfan Liu, Xueyang Sun, Boya Chen, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 24, pp. 15893-15893
Open Access | Times Cited: 64
Hypoxia, Hypoxia-Inducible Factors and Liver Fibrosis
Beatrice Foglia, Erica Novo, Francesca Protopapa, et al.
Cells (2021) Vol. 10, Iss. 7, pp. 1764-1764
Open Access | Times Cited: 62
MicroRNAs in the Pathogenesis of Nonalcoholic Fatty Liver Disease
Zhiqiang Fang, Guo‐Rui Dou, Lin Wang
International Journal of Biological Sciences (2021) Vol. 17, Iss. 7, pp. 1851-1863
Open Access | Times Cited: 58
Placebo effect on progression and regression in NASH: Evidence from a meta‐analysis
Cheng Han Ng, Jieling Xiao, Wen Hui Lim, et al.
Hepatology (2022) Vol. 75, Iss. 6, pp. 1647-1661
Closed Access | Times Cited: 52
Hepatic Stellate Cell-Immune Interactions in NASH
James K. Carter, Scott L. Friedman
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 51

Scroll to top